

AMENDMENTS TO THE CLAIMS

The following is a complete, marked-up listing of revised claims with a status identifier in parenthesis, underlined text indicating insertions, and strike through and/or double-bracketed text indicating deletions.

LISTING OF CLAIMS

1-7. (Cancelled).

8. (Currently Amended) A pharmaceutical composition comprising at least one of tetrahydrofolate, methylene-tetrahydrofolate, and methyl-tetrahydrofolate, and at least one multi-targeting antifolate selected from the group consisting of pemetrexed, raltitrexed and lometrexol.

9. (Currently Amended) A pharmaceutical composition according to claim 8, wherein at least 60% by weight of said at least one of tetrahydrofolate [THF], methyl-THF and methylene-THF is in the form of a biologically active isomer.

10. (Previously Presented) A pharmaceutical composition according to claim 8, wherein said multi-targeting antifolate is selected from the group consisting of pemetrexed, raltitrexed, and lometrexol.

11. (Previously Presented) A pharmaceutical composition according to claim 8, further comprising at least one chemotherapeutic agent selected from

the group consisting of anthracyclines, platinum derivatives, topoisomerase inhibitors, and antimetabolites.

12. (Previously Presented) A pharmaceutical composition according to claim 8, wherein said at least one of tetrahydrofolate, said methylene-tetrahydrofolate and said methyl-tetrahydrofolate, and said at least one multi-targeting antifolate, are formulated in different pharmaceutical compositions.

13. (Currently Amended) A pharmaceutical composition according to claim 8, wherein said at least one of tetrahydrofolate, said methylene-tetrahydrofolate and said methyl-tetrahydrofolate, and said at least one multi-targeting antifolate, are formulated in ~~a common~~ the same pharmaceutical composition.

14. (Currently Amended) A kit comprising a pharmaceutical composition ~~comprising~~ including at least one of tetrahydrofolate, methylene-tetrahydrofolate, and methyl-tetrahydrofolate, and a pharmaceutical composition ~~comprising~~ including at least one multi-targeting antifolate selected from the group consisting of pemetrexed, raltitrexed and lometrexol.

15. (Previously Presented) A kit according to claim 14, wherein at least 60% by weight of said at least one of tetrahydrofolate, methylene-tetrahydrofolate and methyl-tetrahydrofolate is in the form of a biologically active isomer.

16. (Previously Presented) A kit according to claim 14, further comprising a pharmaceutical composition comprising at least one chemotherapeutic agent selected from the group consisting of anthracyclines, platinum derivatives, topoisomerase inhibitors, and antimetabolites.

17. (Currently Amended) A method for ~~the treatment~~ in order to alleviate the symptoms of cancer comprising administering to a patient a pharmaceutically active amount of at least one of tetrahydrofolate, methylene-tetrahydrofolate, and methyl-tetrahydrofolate, and a pharmaceutically active amount of at least one multi-targeting antifolate selected from the group consisting of pemetrexed, raltitrexed and lometrexol.

18. (Previously Presented) A method according to claim 17, wherein at least 60% by weight of said at least one of tetrahydrofolate, methylene-tetrahydrofolate and methyl-tetrahydrofolate is in the form of a biologically active isomer.

19. (Previously Presented) A method according to claim 17, wherein said multi-targeting antifolate is selected from the group consisting of pemetrexed, raltitrexed, and lometrexol.

20. (Currently Amended) A method according to claim 17, further comprising administering a pharmaceutically active amount of a

~~chemotherapeutic~~-chemotherapeutic agent selected from the group consisting of anthracyclines, platinum derivatives, topoisomerase inhibitors, and antimetabolites.

21. (Previously Presented) A method according to claim 17, wherein said at least one of tetrahydrofolate, said methylene-tetrahydrofolate and said methyl-tetrahydrofolate, and said at least one multi-targeting antifolate, are administered consecutively.

22. (Previously Presented) A method according to claim 17, wherein said at least one of tetrahydrofolate, said methylene-tetrahydrofolate and said methyl-tetrahydrofolate, and said at least one multi-targeting antifolate, are administered simultaneously.

23. (Previously Presented) A method according to claim 17, wherein said cancer is selected from the group consisting of breast cancer, gastric cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, and mesothelioma cancer.

*** END CLAIM LISTING ***